TY - JOUR
T1 - Camonco 2
T2 - Results From a Randomized Controlled Trial Comparing Open Dialogue About Complementary Alternative Medicine and Standard Care on Patients' Quality of Life
AU - Stie, Mette
AU - Timm, Signe
AU - Delmar, Charlotte
AU - Nørgaard, Birgitte
AU - Jensen, Lars Henrik
PY - 2024/12/19
Y1 - 2024/12/19
N2 - The rising prevalence of complementary alternative medicine (CAM), including for example, dietary supplements, massage, and acupuncture, among patients with cancer underscores the necessity of integrating open dialogue about complementary alternative medicine (OD-CAM) into oncology treatment and care. PURPOSE This randomized controlled trial aimed to investigate the impact of OD-CAM on patients’ quality of life (QoL), emotional well-being, decision regret, and survival. Patients undergoing antineoplastic treatment were randomly allocated to receive standard care (SC) plus OD-CAM or SC alone. The primary end point was patient-reported QoL 8 weeks after enrollment. Secondary end points included patient-reported QoL, anxiety, depression, and decision regret at 12 and 24 weeks after enrollment and overall survival at 52 weeks after enrollment. MATERIALS Patient-reported outcomes were evaluated using the European Organisation for AND METHODS Research and Treatment of Cancer Computer Adaptive Test Core questionnaire, the Hospital Anxiety and Depression questionnaire, and the Decision Regret Scale. RESULTS A total of 210 patients were equally randomly assigned, leaving 105 patients in each group. No significant differences were observed in QoL, well-being, decision regret, or survival between the groups. CONCLUSION OD-CAM did not demonstrate superiority over SC in enhancing the QoL and well-being of patients undergoing antineoplastic treatment. Increased levels of anxiety and fatigue might result from OD-CAM, underscoring the importance of the person-oriented approach inherent in OD-CAM. OD-CAM may hold clinical significance, especially for those already inclined toward CAM; however, further investigation into the essential components of OD-CAM and the characteristics of patients who are most likely to experience significant improvements of OD-CAM is recommended.
AB - The rising prevalence of complementary alternative medicine (CAM), including for example, dietary supplements, massage, and acupuncture, among patients with cancer underscores the necessity of integrating open dialogue about complementary alternative medicine (OD-CAM) into oncology treatment and care. PURPOSE This randomized controlled trial aimed to investigate the impact of OD-CAM on patients’ quality of life (QoL), emotional well-being, decision regret, and survival. Patients undergoing antineoplastic treatment were randomly allocated to receive standard care (SC) plus OD-CAM or SC alone. The primary end point was patient-reported QoL 8 weeks after enrollment. Secondary end points included patient-reported QoL, anxiety, depression, and decision regret at 12 and 24 weeks after enrollment and overall survival at 52 weeks after enrollment. MATERIALS Patient-reported outcomes were evaluated using the European Organisation for AND METHODS Research and Treatment of Cancer Computer Adaptive Test Core questionnaire, the Hospital Anxiety and Depression questionnaire, and the Decision Regret Scale. RESULTS A total of 210 patients were equally randomly assigned, leaving 105 patients in each group. No significant differences were observed in QoL, well-being, decision regret, or survival between the groups. CONCLUSION OD-CAM did not demonstrate superiority over SC in enhancing the QoL and well-being of patients undergoing antineoplastic treatment. Increased levels of anxiety and fatigue might result from OD-CAM, underscoring the importance of the person-oriented approach inherent in OD-CAM. OD-CAM may hold clinical significance, especially for those already inclined toward CAM; however, further investigation into the essential components of OD-CAM and the characteristics of patients who are most likely to experience significant improvements of OD-CAM is recommended.
U2 - 10.1200/OP.24.00345
DO - 10.1200/OP.24.00345
M3 - Journal article
C2 - 39700437
SN - 2688-1527
JO - JCO Oncology Practice
JF - JCO Oncology Practice
M1 - OP2400345
ER -